Fondaparinux sodium|114870-03-0|(磺达肝癸钠; Fondaparin sodium; SR-90107A)-陌孚医药/Medlife

您当前的位置：

Fondaparinux sodium (Synonyms: 磺达肝癸钠; Fondaparin sodium; SR-90107A)

目录号: PL05377 纯度: ≥98%

CAS No. :114870-03-0

商品编号	规格	价格	会员价
PL05377-5mg	5mg	¥1285.00	请登录
PL05377-10mg	10mg	¥2330.00	请登录
PL05377-25mg	25mg	¥5143.00	请登录
PL05377-50mg	50mg	¥8679.00	请登录
PL05377-100mg	100mg	询价	询价
PL05377-200mg	200mg	询价	询价
PL05377-10mM*1mLinWater	10mM*1mLinWater	¥4455.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Fondaparinux sodium
中文别名	磺达肝癸钠;磺达肝癸钠含量 USP标准品;磺达肝癸钠鉴定 USP标准品;磺达肝素钠;磺达肝素钠鉴定;磺达肝素(癸)钠;FONDAPARINUX SODIUM 磺达肝癸钠;磺达肝癸钠 40MG;黄达肝葵那杂质
英文名称	Fondaparinux sodium
英文别名	Fondaparinux sodium;decasodium (2R,3S,4S,5R,6R)-3-[(2R,3R,4R,6R)-5-[(2R,3R,4S,5S,6S)-6-carboxylato-5-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-oxan-2-yl]oxy-3-(sulfonatoamino)-4-sulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxane-2-carboxylate;FONDAPARINUX SODIUM SALT;Fondaparin sodium;SR-90107A;Fondaparinux sodium solution;Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-β-D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-α-D-glucopyranoside 6-(hydrogen sulfate) sodium salt;a-D-Glucopyranoside, methylO-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(1®4)-O-b-D-glucopyranuronosyl-(1®4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(1®4)-O-2-O-sulfo-a-L-idopyranuronosyl-(1®4)-2-deoxy-2-(sulfoamino)-,6-(hydrogen sulfate), decasodium salt (9CI);Arixtra;IC 85158;IC 851589;Org 31540;SR 90107A;Xantidar;D01844;Arixtra (tn);Fondaparinux sodium N-4;Fondaparinux (sodium salt);Fondaparinux sodiuM(D01844);Fondaparinux and intermediates;Fondaparinux sodium, >=98%;Quixidar;X0Q6N9USOZ;fondaparinux-sodium;Fondaparinux sodium [USAN:INN:BAN];Fondaparinux sodium (JAN/USAN/INN);alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-al;Fondaparinux sodium for assay;Fondaparinux sodium identification;Methly O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a
Cas No.	114870-03-0
分子式	C₃₁H₄₃N₃Na₁₀O₄₉S₈
分子量	1728.08
包装储存	4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

产品详情

Fondaparinux sodium 是一种抗凝血酶依赖性的 factor Xa 抑制剂。

生物活性

Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

性状

Solid

IC50 & Target[1][2]

Factor Xa

体外研究(In Vitro)

Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs). has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ClinicalTrial

参考文献

[1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.
[2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

溶解度数据	In Vitro: H₂O : 125 mg/mL (72.33 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation